Posted On: 04/05/2013 2:35:03 PM
Post# of 102825
$BMSN - WHY WE EXIST
Currently there is a major inefficiency in the development of stem cell therapies: companies are set up, large costs are spent on infrastructure development, then when the product fails everything goes to waste. Our approach is to establish an infrastructure that can be used for multiple therapeutic products.
Valentina Goncharovna Conducting
Pre-clinical Research
(0)
(0)
